FDA grants precedence evaluation to an NDA for taletrectinib in ROS1+ NSCLC.
The Meals and Drug Administration (FDA) has accepted a brand new drug utility (NDA) with precedence evaluation for the investigational next-generation ROS1 tyrosine kinase inhibitor (TKI) taletrectinib within the remedy of superior ROS1-positive non–small cell lung most cancers (NSCLC), in response to a information launch from Nuvation Bio Inc. Notably, the applying has a Prescription Drug Person Charge Act (PDUFA) motion date of June 23, 2025.
The NDA relies on the pooled outcomes from the pivotal section 2 TRUST-I medical trial, which was performed in China, in addition to the TRUST-II world examine, each of which investigated taletrectinib. Knowledge on the agent have been shared on the 2024 ESMO Congress in September.
“We’re thrilled to succeed in this necessary milestone for taletrectinib, a major step ahead for folks dwelling with ROS1-positive NSCLC who urgently want new remedy choices,” mentioned Dr. David Hung, founder, president and chief government officer of Nuvation Bio, within the information launch. “With knowledge from over 300 sufferers — the biggest ROS1-positive NSCLC dataset thus far supporting an authentic NDA — taletrectinib has demonstrated the potential to ship sturdy and significant advantages.”
Diving Into the TRUST-I and TRUST-II Medical Trials
The section 2 medical trials evaluated the ROS1 TKI in 337 sufferers with superior ROS1-positive NSCLC. These sufferers obtained taletrectinib at a dose of 600 mg orally as soon as every day in 21-day cycles. The first finish level of those research is confirmed goal response charge (cORR) as assessed by an impartial evaluation committee, whereas key secondary finish factors embrace intracranial cORR, period of response (DOR), progression-free survival (PFS) and security.
Within the knowledge shared on the ESMO Congress, investigators famous that in sufferers with superior ROS1-positive NSCLC who have been TKI-naive and in sufferers who have been TKI-pretreated, tumors shrank in 89% and 56% of sufferers, respectively. Moreover, the agent demonstrated sturdy responses and extended PFS. The median DOR was 44 months in TKI-naive sufferers and the median PFS was 46 months in the identical affected person group. Moreover, the agent had a positive security and tolerability profile.
Extra Data on the Use of Taletrectinib
Multiple million folks globally are identified with NSCLC yearly, and roughly 2% of these have ROS1-positive mutations. Of those sufferers, 35% have tumors that unfold to their mind, which will increase to 55% for these whose most cancers has progressed following first-line remedy, in response to the information launch. In flip, this creates an unmet want for sufferers. The information launch notes that this precedence evaluation designation of taletrectinib underscores the developments that the agent could supply for this affected person inhabitants.
Glossary:
Breakthrough Remedy Designation: a course of that quickens the event and evaluation of medicine for severe situations.
Confirmed Goal Response Charge (cORR): the share of sufferers in a examine who’ve a confirmed finest goal response to a remedy.
Period of Response (DOR): the period of time a affected person responds to remedy with out their most cancers rising or spreading.
New Drug Software (NDA): a request to approve a brand new drug on the market and advertising in the US.
Orphan Drug Designation: a standing given to medicine which are being developed to deal with uncommon illnesses or situations.
Prescription Drug Person Charge Act (PDUFA): a regulation that enables the FDA to gather charges from firms that submit sure human drug purposes for evaluation.
Development-Free Survival (PFS): a measure utilized in medical trials to guage the effectiveness of most cancers therapies.
ROS1 TKI: a drug that treats cancers brought on by the ROS1 gene, which encodes a receptor tyrosine kinase.
The Meals and Drug Administration (FDA): a federal company that protects the general public’s well being.
Taletrectinib, which is an oral, potent, central nervous system-active, selective agent, beforehand obtained orphan drug designation from the FDA and is presently the one ROS1 TKI in growth that has obtained breakthrough remedy designation from the FDA for the remedy of sufferers with regionally superior or metastatic ROS1-positive NSCLC.
For extra information on most cancers updates, analysis and schooling, don’t neglect to subscribe to CURE®’s newsletters right here.
